Introduction
============

It is now well accepted that the microbiota present in the human body can impact immunity, physiology, and health ([@B43]). It has been postulated that the unique vaginal microbiome has evolved to perform the dual roles of disease resistance and obstetric protection ([@B2]). Moreover, infections can arise from imbalances in the highly diverse vaginal microbiota (e.g., VVC). VVC, caused primarily by *Candida*, is the second-most common vaginal infecti and is associated with vulval discomfort or and pain ([@B15]). The recommended standard therapy for vaginal *C. albicans* infections is antifungal therapy, consisting of oral or intravaginal azole, or triazole drugs ([@B42]). However, prolonged use of antibiotic administration increases recurrence rates, probably due to an inability to re-establish the normal *Lactobacillus*-dominated vaginal flora.

In recent years there has been growing interest in the therapeutic use of probiotics. *Lactobacillus* species in general are recommended as a new strategy, which is increasing in popularity based on accumulating evidence for their effectiveness in restoring normal microbial function and preventing urogenital infections ([@B2]). Probiotic use has been associated with a significant reduction in the recurrence of VVC ([@B36]). First introduced in 1974 by Parker ([@B17]), the word "probiotic" is used to describe live microorganisms that provide a benefit to the recipient when administered in sufficient quantities ([@B48]).

The vaginal microbiota in most healthy women of reproductive-age is dominated by protective *Lactobacillus* species that are thought to reinforce the defense against invasion and colonization by pathogenic microorganisms ([@B32]). In women with vaginal infections, such as BV and VVC, the dominance of these *Lactobacilli* is compromised ([@B41]). Consequently, intravaginal probiotics of the *Lactobacillus* genus are common and act beneficially in a number of ways. In addition to their function as a barrier to vaginal colonization by harmful microorganisms ([@B24]), these species maintain an acidic intravaginal microflora by generating lactic acid via carbohydrate decomposition ([@B9]), inhibit catalase-negative anaerobic organisms by production of hydrogen peroxide (H~2~O~2~) as a source of free radicals ([@B26]) and produce antimicrobial peptides, such as bacteriocin-like substances and biosurfactants ([@B47]). In addition, *Lactobacillus* species induce anti-inflammatory immune responses in the host via the NF-κB pathway ([@B39]).

More than 20 species of *Lactobacilli* have been detected in the vagina, of which *L. crispatus* is the most prevalent in healthy Asian women and has been widely investigated as a vaginal probiotic due to its strong antimicrobial activity ([@B37]).

*Lactobacillus crispatus* confers protection on the epithelial barrier against injury and inflammation by regulating epithelial cell function ([@B3]). Our previous study showed that *L. crispatus* attenuates the virulence of *C. albicans*, modulates the secretion of cytokines and chemokines, and enhances the immune response of VK2/E6E7 cells *in vitro* ([@B33]). However, there are no commercially available vaginal preparations containing *L. crispatus* in the Chinese market. Live *Lactobacillus* Capsule for Vaginal Use, containing *L. delbrueckii* (Neimenggu Wanzeshuangqi Pharmaceutical Co., Ltd.) is the only commercial preparation of *Lactobacillus* that is currently available. This preparation has been introduced to inhibit the cytotoxic effects and adhesion of pathogenic organisms ([@B4]). *L. delbrueckii* produces large amounts of H~2~O~2~ and has been reported to inhibit *C. albicans* more effectively than many other vaginally derived strains found in healthy women ([@B45]). Due to the close anatomic relationship with the vagina, the anus is convenient for the migration of gut organisms, including oral administration of probiotic *Lactobacillus* strains (e.g., yogurt drinks), to the vagina. Passive transfer of *Lactobacilli* to the vagina from the rectum may be an important consideration in the delivery of probiotics in foods and dietary supplements ([@B8]). Intake of oral probiotics containing *Lactobacillus* strains improved the recovery rate and symptoms of patients with vaginal infections and tended to improve the vaginal microbial pattern ([@B27]).

Considering the proven health promoting effects of *L. crispatus*, investigations of the efficacy of topical *Lactobacillus* strains on treatment of VVC are warranted. To date, few, if any, studies have assessed the anti-*Candida* activities and probiotic properties of *Lactobacillus* strains in VVC. Therefore, the objective of this study was to investigate and compare the effects of (1) *L. crispatus* as the predominant vaginal bacteria in humans, and (2) *L. delbrueckii*, which is contained in the only commercially available vaginal preparation of *Lactobacillus* strains, to prevent the invasion of *C. albicans*, additionally focusing on the immune response of the host vaginal epithelium in a rat model.

Materials and Methods
=====================

Microorganism and Growth Conditions
-----------------------------------

*Lactobacillus crispatus* \[American Type Culture Collection (ATCC) 33820\] was routinely cultured anaerobically at 37°C in de Man, Rogosa and Sharpe broth (Becton Dickinson, Cockeysville, MD, United States). After overnight culture, cells were collected by centrifugation (10,000 × *g*, 10 min, 5°C), washed twice, and resuspended in 0.9% saline solution at 3 × 10^8^ CFU/ml. The vaginal *Lactobacillus* (Dingjunsheng^®^; Neimenggu Wanzeshuangqi Pharmaceutical Co., Ltd.) probiotic preparation consisted of 0.25 g capsules containing approximately 0.25 × 10^6^ CFU of live *L. delbrueckii*. Suspensions were formulated daily in saline solution to achieve approximately 3 × 10^8^ CFU/ml. *L. crispatus* or *L. delbrueckii* suspensions were administered intravaginally to each animal once daily at 3 × 10^8^ CFU/ml.

*Candida albicans* strains (ATCC-11006) were cultured to the third generation on Sabouraud dextrose agar (SDA; Becton Dickinson) at 37°C for 72 h and harvested. After resuspension in 0.9% saline solution, the cells were counted using a hemocytometer (Hausser Scientific; Horsham, PA, United States) and adjusted to a final concentration of 1 × 10^5^ CFU/ml.

Animals
-------

Female Sprague--Dawley rats (*n* = 24, 210--240 g), obtained from Beijing Vital River Laboratory Animal Technology Co. Ltd. (Beijing, China), were maintained in cages under a 12-h light/ 12-h dark cycle with free access to commercial food and water.

Experimental Candidal Vaginitis
-------------------------------

The timeline of the experimental animal treatment and sample collection is shown in [Figure 1](#F1){ref-type="fig"}. Prior to infection, animals received subcutaneous injection of 0.5 mg estradiol benzoate (Estradiolo, Amsa Farmaceutici, Rome, Italy) at 2-day intervals until the end of the experiment to induce immunosuppression ([@B52]). The hormonal activity was assessed by analysis of the enucleated epithelial cells in vaginal fluid smears verified under a light microscope; enucleated cornified cells indicated the pseudo-estrus phase ([@B30]). The rats were inoculated intravaginally with a yeast suspension of 1 × 10^8^ yeasts/mL (in 150 mL of sterile saline solution) of washed *C. albicans* blastoconidia. Four days after inoculation but before treatment, samples were obtained from the vaginal cavity to confirm *C. albicans* infection by Gram staining of the yeast/hyphae-like form and vaginal cells observed under light microscopy.

![Timeline of the experimental animal treatment and sample collection.](fmicb-10-01033-g001){#F1}

The rats were randomly divided into four groups (*n* = 6 rats per group). At 24 h after the initial infection, rats were randomly divided into following four groups (*n* = 6 rats per group); (a) uninfected (Control, vaginal inoculation with 0.9% saline solution); (b) infected (Model, vaginal inoculation with 0.9% saline solution); (c) infected but received intravaginal *L. crispatus* (approximately 3.0 × 10^8^ CFU/mL) once a day for 7 days; and (d) infected but received intravaginal *L. delbrueckii* (approximately 3.0 × 10^8^ CFU/mL) once a day for 7 days. At 1 (Day 28) and 4 days (Day 31) after the 7-day treatment period, a microbiological evaluation was performed by Gram staining. The *C. albicans* load in vaginal lavage (two sequential 500 μl volumes of sterile saline) was determined by the CFU assay on SDA. The antifungal effects were analyzed by enumerating the CFU/mL within the samples. All rats were anesthetized with an intraperitoneal injection of 100 mg/kg of ketamine hydrochloride and euthanized. Whole-vagina samples were harvested.

Histological Analysis
---------------------

Following immersion in formalin, vaginal samples were cut into 4-μm thick sections and stained using a HE staining kit (Beyotime Biotechnology, Beijing, China) according to the manufacturer's instructions. The tissues were then dehydrated by immersion in a gradient alcohol series followed by xylene clearing. After sealing with a neutral balsam, the tissues were evaluated for pathological changes under a microscope (Olympus).

Immunohistochemistry
--------------------

Sections were incubated overnight at 4°C with the following primary detection antibodies: anti-rat-IFN-γ (1:100), anti-rat-IL-4 (1:200), anti-rat-IL-17 (1:50) (all rabbit polyclonal, Cloud-Clone, United States), and anti-IgG (RP215, provided by the Immunology Department, Peking University Health Science Center; 1:100). Sections were then incubated with horseradish peroxidase-conjugated anti-rabbit Ig (Zhongshan Golden Bridge Biotechnology) and immunoreactivity was developed using the 3,3′-diaminobenzidine (DAB) substrate system. Negative control sections were incubated with PBS instead of the primary antibody. Semi-quantitative analysis was performed by an experienced pathologist based on IRS ([@B14]) calculated by multiplying SP scores: 0, \<10%; 1, 10--25%; 2, 26--50%; 3, 51--75%; 4, 76--100%) and SI scores: 0, negative; 1, mild; 2, moderate; 3, severe).

Transmission Electron Microscopy (TEM) Examination
--------------------------------------------------

Vaginal tissue pieces were removed, fixed (3% glutaraldehyde and 1% osmium tetroxide), dehydrated in a graded ethanol series and embedded in a PON812 resin (SPI, West Chester, PA, United States). Tissues were. then stained with 5% uranyl acetate and lead citrate. Ultrastructural changes in the vaginal tissues were observed under a JEM 1230 TEM (JEOL Co., Hitachi Ltd., Tokyo, Japan) and photographed.

Desmosomes within the epithelium were identified and enumerated by two independent investigators according to a previously described method ([@B10]). Desmosomes were identified and quantified as discrete, linear hyper-densities along the outer cellular membrane that confer structural integrity to tissues. Additional morphological features of the epithelia were identified independently by two investigators.

Statistical Analysis
--------------------

All data were analyzed using statistical analysis software SPSS 13.0. Data represent the mean ± standard deviation (*n* = 6 animals per group) of three independent experiments. Quantitative variables were tested for normal distribution and data were compared using a single-factor analysis of variance (ANOVA) using Windows software (SPSS Inc., Chicago, IL, United States). Fisher's LSD test was used to evaluate differences between two groups. *P* \< 0.05 was considered to indicate statistical significance.

Results
=======

*L. crispatus* and *L. delbrueckii* Protect Against *C. albicans* in VVC Rats
-----------------------------------------------------------------------------

To compare the antifungal effects of *L. crispatus* and *L. delbrueckii*, rats were infected intravaginally with the mucosal *C. albicans*. At 1 and 4 days after the last dose, samples were obtained from all animals, and assessed by Gram staining. The results showed that vaginal administration of *L. crispatus* or *L. delbrueckii* exerted similarly, weak anti-*C. albicans* vaginitis effects. Among the untreated Model rats that remained infected, all vaginal swabs tested positive for *C. albicans*, with the epithelial cells being penetrated by the hypha (Day 31, [Figure 2A](#F2){ref-type="fig"}). However, two of the six rats with positive vaginal swabs were Gram stain-negative after receiving intravaginal *L. crispatus* or *L. delbrueckii* (Day 31), suggesting less than half of the infected rats were cured. The negative pathogen conversion rate of *L. crispatus* at 1 (Day 28) and 4 days (Day 31) after treatment reached 33.3% (2/6), and 33.3% (2/6), respectively, and there were no significant differences compared with the negative pathogen conversion rate of the corresponding *L. delbrueckii* groups \[0% (0/6) at 1 day (Day 28) and 33.3% at 4 days (Day 31) after treatment; *P \>* 0.05; [Figures 2B--D](#F2){ref-type="fig"}\].

![Gram staining of a vaginal swab from Model **(A)** and *Lactobacilli*-treated rats **(B--D)**. *Candida albicans* hypha (black arrow) adhering to vaginal epithelial cells. The probiotic *Lactobacilli* surround and inhibit the growth of *C. albicans* hyphae. Scale bar = 20 μm, magnification × 1,000. Model (without treatment); *L. crispatus* treated (3.0 × 10^8^ CFU for 7 days, Gram stain-positive); *L. delbrueckii* treated (3.0 × 10^8^ CFU for 7 days, Gram stain-positive); and Cured (3.0 × 10^8^ CFU of *L. crispatus* for 7 days, Gram stain-negative).](fmicb-10-01033-g002){#F2}

Next, we assessed the antifungal effects of intravaginal *L. crispatus* or *L. delbrueckii* on the fungal burden by quantifying the colony formation ([Figure 3](#F3){ref-type="fig"}). At baseline, Control rats were free of *C. albicans*. The mean CFU/mL for *C. albicans* at Day 28 was 49.00 ± 2.77 × 10^3^ in the Model group at Day 28, and was followed by a slow decline in vaginal *Candida* burden to 34.17 ± 3.78 × 10^3^ at Day 31. One day after the treatment (Day 28), the mean CFUs in the *L. crispatus* (14.00 ± 4.73 × 10^3^) and *L. delbrueckii* (18.17 ± 2.24 × 10^3^) groups were significantly lower than those in the Model group ([Figure 3A](#F3){ref-type="fig"} and [Table 1](#T1){ref-type="table"}; *P* \< 0.001). Four days after the treatment (Day 31), the mean CFUs in the *L. crispatus* (9.33 ± 3.42 × 10^3^), and *L. delbrueckii* (12.17 ± 4.58 × 10^3^) groups were significantly lower than those the Model group ([Figure 3B](#F3){ref-type="fig"} and [Table 1](#T1){ref-type="table"}; *P* \< 0.001). There were no significant differences in the mean CFUs in the *L. crispatus*, and *L. delbrueckii* groups at one (Day 28) or 4 day (Day 31) after the treatment (*P \>* 0.05).

![The number of colony-forming units (CFU)/mL of samples of vaginal tissue obtained from rats (**n** = 6 rats/group) at 1 day **(A)** and 4 days **(B)** after treatment and incubated on Sabouraud dextrose agar. Uninfected female Sprague-Dawley rats were used as controls. Model rats were infected with 1 × 10^8^ CFU/ml **C. albicans**. Control (uninfected); Model: infected with 1 × 10^8^ CFU/ml **C. albicans**;**L. crispatus** treated: infected and treated with **L. crispatus** 3.0 × 10^8^ CFU for 7 days; **L. delbrueckii**treated: infected and treated with **L. delbrueckii** 3.0 × 10^8^ CFU for 7 days.](fmicb-10-01033-g003){#F3}

###### 

Number of uninfected animals and quantification of fungal burden.

  Treatment groups                                            Control       Model          *L. crispatus*   *L. delbrueckii*   *P*-value
  -------------------------------- -------------------------- ------------- -------------- ---------------- ------------------ -----------
  Day 1 after treatment (Day 28)   CFU/mL (×10^3^)            0.00 ± 0.00   49.00 ± 2.77   14.00 ± 4.73     18.17 ± 2.24       \<0.001
                                   Uninfected rats (N/n)^a^   6/6           0/6            2/6              0/6                
  Day 4 after treatment (Day 31)   CFU/mL (×10^3^)            0.00 ± 0.00   34.17 ± 3.78   9.33 ± 3.42      12.17 ± 4.58       \<0.001
                                   Uninfected rats (N/n)      6/6           0/6            2/6              2/6                

a

N, number of uninfected animals/n: total animals per group.

Morphometric Analysis
---------------------

We performed HE staining and TEM analyses of anatomical and ultrastructural changes to evaluate the probiotic properties of the two *Lactobacillus* strains. The epithelium and mucosa in uninfected Control animals appeared normal, with no signs of inflammation, and a thick layer of stratum corneum was observed in the vaginal canal. All Model animals presented abnormal vaginal discharge and tissue swelling, as well as severe inflammation of the epithelium following *Candida* infection. HE staining revealed serious damage to the vaginal mucosa, with epithelial cell exfoliation and inflammatory cell infiltration, following infection with *C. albicans* ([Figure 4A](#F4){ref-type="fig"}). Compared to the Model animals mucosa, the animals treated with *L. crispatus* or *L. delbrueckii* for 7 days showed a significant alleviation of inflammation and damage to the vaginal epithelial mucosa. In addition, an almost complete restoration of the mucosa was observed although some inflammatory cells persisted on the surface of the mucosa and in the lamina propria ([Figures 4B,C](#F4){ref-type="fig"}). Several damaged tissues were observed with a complete restoration of a healthy vaginal mucosa ([Figure 4D](#F4){ref-type="fig"}).

![Histology of vaginal tissue sections from Model **(A)** and **Lactobacilli**-treated rats **(B--D)**, stained with hematoxylin-eosin. Damaged vaginal epithelium (blue arrow), exfoliated vaginal epithelial cells (red box), and neutrophils (yellow arrow) infiltrating the vaginal epithelium are shown. Scale bar = 50 μm. Model (without treatment);**L. crispatus**-treated (3.0 × 10^8^ CFU for 7 days, with neutrophil infiltration); **L. delbrueckii**-treated (3.0 × 10^8^ CFU for 7 days, with neutrophil infiltration); and Cured (3.0 × 10^8^ CFU of **L. crispatus** for 7 day, without neutrophil infiltration).](fmicb-10-01033-g004){#F4}

*L. crispatus* and *L. delbrueckii* Promote the Integrity of the Ultrastructural Morphology of the Vaginal Mucosal Barrier
--------------------------------------------------------------------------------------------------------------------------

Under TEM observation, the normal vaginal mucosal barrier consists of tightly packed stratified squamous non-keratinized epithelial cells (i.e., desmosomes, as rigid plaques that maintain tissue integrity and intercellular adhesion) with numerous intact finger-like and/or bubble-like pseudopods or microvilli on their surface ([Figures 5A,B](#F5){ref-type="fig"}). The usual structure of desmosomes is clearly identified by the presence of outer and inner dense plaques on the cytoplasmic side of the plasma membrane. After *C. albicans* infection, neutrophils and spores infiltrating the vaginal epithelium and lamina propria were observed. In accordance with a previous study ([@B20]), histological evaluation showed that the intracellular spaces were enlarged, desmosomal junctions were significantly impaired and blurred, and cytoplasmic vacuolization was present in non-keratinocytes and intercellular disjunctions ([Figures 5C,D](#F5){ref-type="fig"}). The number of desmosomes per cell was significantly reduced in epithelia after challenge compared with that in normal epithelia (43.67 ± 8.43 vs. 12.33 ± 4.32, *P* \< 0.0001). Intracellularly, mitochondria exhibited swelling, as well as crest deformation and dissolution. Furthermore, compared with the Model group, we observed a marked ultrastructural improvement in the vaginal epithelium following treatment with either of the *Lactobacillus* strains, with significant reductions in the numbers of adhesive yeast, desmosome-like junctions and hyphal forms. The morphology of the mitochondria was normal or showed only slight swelling in the *L. crispatus* ([Figures 5E,F](#F5){ref-type="fig"}) or *L. delbrueckii* groups ([Figures 5G,H](#F5){ref-type="fig"}) when compared with that in the Model groups. The number of desmosomes in the *L. crispatus* group was significantly increased compared with that in the Model group (34.67 ± 7.61, *P* \< 0.0001; [Figure 6](#F6){ref-type="fig"}). Moreover, the number of desmosomes in the *L. delbrueckii* group (37.83 ± 6.97) was almost the same as that observed in normal epithelia ([Figure 6](#F6){ref-type="fig"}; *P* = 0.443). These observations indicated that *Lactobacillus* induced a partial restoration of the mucosa.

![Ultrastructural changes in the vaginal mucosa of rats observed by transmission electron microscopy. Control, uninfected **(A,B)**; Model, infected with 1 × 10^8^ CFU/ml *C. albicans* **(C,D)**; *L. crispatus* treated, infected and treated with *L. crispatus* 3.0 × 10^8^ CFU for 7 days **(E,F)**; *L. delbrueckii* treated, infected and treated with *L. delbrueckii* 3.0 × 10^8^ CFU for 7 days **(G,H)**. Rats in the Control group show normal vaginal morphology with a non-keratinized stratified squamous epithelium and intact microvilli (black arrow) extended by vaginal epithelial cells. Yeast cells (blue arrow) invading the superficial layers of the vaginal mucosa, with injured desmosome-like junctions (yellow arrow) and swollen mitochondria (M) after infection with 1 × 10^8^ CFU/ml *C. albicans*.](fmicb-10-01033-g005){#F5}

![Desmosome quantification by TEM. Ultrastructure of desmosomes in the vaginal epithelium of rats observed by TEM. Control, uninfected **(A)**; Model, infected with 1 × 10^8^ CFU/ml **C. albicans** **(B)**;**L. crispatus** treated, infected and treated with **L. crispatus** 3.0 × 10^8^ CFU for 7 days **(C)**; **L. delbrueckii**treated, infected and treated with **L. delbrueckii** 3.0 × 10^8^ CFU for 7 days **(D)**. The desmosome-like junctions (yellow arrow) are significantly diminished, and the space between adjoining epithelial cells is widened in Model rats. Number of desmosomes per cell **(E)** in normal Control, Model, **L. crispatus** treated and **L. delbrueckii**treated rats. Data represent the mean ± standard deviation (**n** = 6). \***P** \< 0.05; \*\***P** \< 0.01; \*\*\***P** \< 0.001.](fmicb-10-01033-g006){#F6}

*L. crispatus* and *L. delbrueckii* Modulate Cytokine Release by Vaginal Epithelial Tissue
------------------------------------------------------------------------------------------

Our immunohistochemical studies revealed increased expression of IFN-γ (IRS: 4.17 ± 2.57 vs. 8.17 ± 2.57) and IL-17 (IRS: 4.67 ± 2.07 vs. 6.33 ± 2.88), indicating stimulation of Th 1 and Th 17-type immune responses in the vaginal epithelium following *C. albicans* infection. However, there were no significant differences in the IRS scores for IFN-γ (*P* = 0.055, [Figure 7A](#F7){ref-type="fig"}), IL-4 (*P* = 0.082, [Figure 7B](#F7){ref-type="fig"}), and IL-17 (*P* = 0.017, [Figure 7C](#F7){ref-type="fig"}) among the groups. The IFN-γ/IL-4 ratio was calculated to reflect the Th1/Th2 balance ([Table 2](#T2){ref-type="table"}). When challenged with *C. albicans*, the IFN-γ/IL-4 ratio was significantly higher than that of the untreated animals (0.47 ± 0.24 vs. 1.26 ± 0.87, *P* = 0.012). In contrast, the ratio was significantly lower in the *L. crispatus* group following *in vivo* challenge (0.43 ± 0.26, *P* = 0.009) compared than that in the *L. delbrueckii* group (0.80 ± 0.36, *P* = 0.219), for which the ratio was similar to that of the normal tissue (*P \>* 0.05).

![The expression of IFN-γ, IL-4 and IL-17 in vaginal tissues. Semi-quantitative analysis by immunoreactivity score (IRS) of IFN-γ, IL- 4 and IL-17 detected by immunohistochemistry. Control, uninfected **(A)**; Model, infected with 1 × 10^8^ CFU/ml *C. albicans* **(B)**; *L. crispatus* treated, infected and treated with *L. crispatus* 3.0 × 10^8^ CFU for 7 days **(C)**; *L. delbrueckii* treated, infected and treated with *L. delbrueckii* 3.0 × 10^8^ CFU for 7 days **(D)**. Data represent the mean ± standard deviation (*n* = 6). Scale bar = 50 μm.](fmicb-10-01033-g007){#F7}

###### 

Immunoreactivity score (IRS) of Th1/Th2 ratio (IFN-γ/IL-4) (*n* = 6, ANOVA).

  Th1/Th2            IRS scores       *F*-value   *P*-value
  ------------------ ---------------- ----------- -----------
  Control            0.47 ± 0.24^a^   3.563       0.033
  Model              1.26 ± 0.87                  
  *L. crispatus*     0.43 ± 0.26^a^               
  *L. delbrueckii*   0.80 ± 0.36                  

a

P

\< 0.05 compared to Model.

Although the vaginal mucosa acts a barrier against pathogenic invasion, there is no direct evidence that vaginally expressed Ig molecules contribute to antimicrobial activity. The monoclonal antibody RP215 binds specifically to a unique glycosylated epitope on non-B cell, epithelial-derived IgG. Strong R215-positive staining was detected in the cytoplasm of normal vaginal epithelial cells, while staining in the submucosa tissue was weak. There were significant differences in the IRS scores for epithelial-derived IgG among the groups (*P* = 0.006, [Figure 7D](#F7){ref-type="fig"}). The IRS score for epithelial IgG secreted by the vaginal mucosa was 10.50 ± 2.51, which dropped sharply following infection (6.67 ± 3.27; *P* = 0.010). However, when treated with *L. crispatus*, the score was significantly increased (10.00 ± 2.19, *P* = 0.022) with a similar pattern observed in the *L. delbrueckii* group (12.00 ± 0.00, *P* = 0.153), which reached the baseline values (*P \>* 0.05).

Discussion
==========

*Lactobacilli* are Gram-positive rod-shaped, lactic acid producing bacteria which are mostly obligate and facultative anaerobes and predominantly found in the human genitourinary tract ([@B19]). The *Lactobacilli* present in the vagina are important in preventing vaginal infections, such as BV and VVC, and invasion by pathogenic microorganisms, including human papillomavirus, and human immunodeficiency virus ([@B38]). The currently available antimicrobial treatments for vaginal infections are associated with incomplete effectiveness leading to recurrent infections, drug resistance, and side-effects; therefore, alternative drugs are urgently required. In recent years, the use of *Lactobacilli*-derived probiotic bacteria has emerged as a novel strategy for the management of vaginal infections. However, investigations of the antifungal activities of probiotic strains are less common than investigations of their antibacterial activities ([@B13]). We have previously demonstrated that probiotic *Lactobacilli* can attenuate the virulence of *C. albicans* by modulating the secretion of cytokines and chemokines and enhancing the innate immune response *in vitro* ([@B33]). The functional characteristics of probiotics should be established based on both *in vitro* and *in vivo* studies. In the present study, intravaginal delivery of *Lactobacillus* strains for 7 days inhibited the *in vivo* growth of *Candida* species by between 60 and 70%. Thus, this animal model provides clear evidence of the fungicidal or candidacidal effects of the two probiotic *Lactobacillus* strains. [@B29] reported that *L. delbrueckii* showed no antimicrobial activity against pathogens, mainly due to the absence of organic acid production. However, in the present study, the antifungal effect of *L. delbrueckii* was similar to that of *L. crispatus*, which is believed to contribute to the control of vaginal microbiota by competing with other microflora for colonization of the vaginal epithelial cells ([@B31]), as well as liberating H~2~O~2~ and other substances that mediate intracellular antifungal activity ([@B44]). These findings indicate the potential of these two probiotic *Lactobacillus* strains as an adjuvant to the mainstay in clinical treatment of VVC. However, the antifungal activity of probiotic *Lactobacillus* strains is very complex and requires further investigation ([@B34]).

Maintaining the vaginal epithelial barrier is crucial as it maintains the balance between commensal microorganisms and the host. One of the potential health benefits of probiotics is the suppression of inflammatory responses ([@B21]). In our present study, upregulation of proinflammatory cytokines by *C. albicans* infection suggested T cell proliferation (IFN-γ and IL-17) and T cell activation ([@B7]), while *Lactobacillus* treatment induced a partial reduction in the Th1/Th2 ratio. These observations suggest that both strains counteract the molecular events leading to T cell activation, as has been shown previously for the probiotic strains *L. paracasei* ([@B7]), *L. plantarum* ([@B7]), and *L. casei* ([@B11]). The two *Lactobacillus* strains used in this study, and particularly *L. crispatus*, were able to alter the cytokine profiles of vaginal epithelial cells, thus redirecting the pattern of immunity to a regulatory or tolerant mode that balances the Th1/Th2 ratio, and suppresses the proinflammatory cytokine production (e.g., IL17 and IFN-γ), although this difference was not statistically significant, which is in accordance with previous reports ([@B46]). Decreased production of IFN-γ, a typical Th1 cytokine, could be a very interesting probiotic feature ([@B7]). Although crucial for innate and adaptive immunity against intracellular pathogens, a prolonged distinct Th1-bias with a persistently high Th1/Th2 ratio leads to cell-mediated cytotoxicity, and inflammatory responses ([@B6]; [@B35]). Taken together, these findings further support the hypothesis that *Lactobacilli* play an important role in maintaining the immune homeostasis by regulating cytokine secretion by epithelial cells ([@B7]), and in this respect, *L. crispatus* treatment was more effective than *L. delbrueckii*. The sensing of, and signaling induced by, *Lactobacilli* require further investigation. *Lactobacillus*-derived proteins ([@B50]) and lactic acid induced acidification may be immunomodulatory functions that suppress the IFN-γ response of immune cells related to the Janus kinase/STAT signaling pathway and inhibit of the production of cytokines that mediate innate immunity ([@B16]).

Previous studies have demonstrated that functional epithelial-derived IgG (RP215 positive) is secreted by vaginal epithelial cells *in vitro*. This finding challenges the classical concept that B cells are the only source of immunoglobulins ([@B28]). These immunoglobulins appear to participate in skin innate immunity ([@B22]) and may serve as natural antibodies (apparently the most controversial branch of humoral immunity), which not only recognize and neutralize antigenic microbial products ([@B2]), but also provide long-term immunological memory that improves standard azole therapy efficacy and prevents relapse ([@B23]). Our animal study confirmed our hypothesis that non-B IgG is expressed in the vaginal epithelium, a response that appears to be diminished by mycotic infections, but can be restored by *Lactobacillus* treatment. Further studies are required to ascertain the molecular mechanism by which *Lactobacilli* participate in the mucosal immunity in the vagina related to epithelial-derived IgG.

Another potential health benefit of *Lactobacillus* treatment is provided by the enhanced epithelial cell survival and barrier function ([@B50]; [@B49]). Ultrastructural analysis by electron microscopy verified several key features of *in vivo* vaginal epithelial tissue, such as the presence of desmosomes and mitochondria. In epithelial tissues, cells are anchored to one another via junctional complexes e.g., desmosomes, to maintain tissue integrity, and protect against the external environment ([@B18]). Infection with pathogenic *C. albicans* not only significantly stimulates inflammatory cells, but also induces significant ultrastructural changes in the host cells, such as inhibited desmosome assembly, eventually leading to reduced adhesive strength ([@B25]). Desmosomes, one of the predominant types of adhesive intercellular junctions in vertebrate tissues, are challenged by a variety of factors such as toxins, pathogens and inflammatory factors, potentially leading to tissue damage ([@B12]). The damage to the epithelia, which could be the consequence of the inflammatory process itself, is related to disruption of this barrier, and passage of pathogenic microorganisms or molecules, an effect that is positively affected by probiotics, which stabilize the barrier function. There are several reports related to the effects of probiotic *Lactobacilli* on the "recovery" of the vaginal mucosa.

*Lactobacilli* have been reported to decrease damage to the DNA of epithelial cells ([@B51]), reduce epithelial permeability, and attenuate the inflammatory response ([@B1]). *Lactobacilli* have also been reported to prevent the attachment of the pathogenic microorganism required to exert its effects on paracellular permeability through upregulating production of MUC3 mucin ([@B1]) and ameliorate epithelial apoptosis by producing *Lactobacillus*-derived soluble proteins in an EGF receptor-dependent manner ([@B50]). Mitochondria are influenced by a multitude of vital signals involved in the regulation of energy metabolism and cellular survival. These signals promote or prevent cell survival by modulating mitochondrial function and structure ([@B40]). Fungal infections directly or indirectly impair mitochondrial ultrastructure, ultimately leading to destruction of the vaginal epithelium. However, in this study, we observed significant improvements in the ultrastructure of the vaginal epithelium and host cell mitochondria following the administration of *Lactobacilli*. *Lactobacilli* exert protective anti-oxidant effects by preventing mitochondrial-generated reactive oxygen species that induce membrane damage ([@B5]).

This study provides evidence implicating *Lactobacilli* as a potential adjunct biotherapeutic agent in women with VVC, especially for those with drug resistance, adverse effects or contraindications when using antifungal agents. The effects of probiotic *L. crispatus* and *L. delbrueckii* in treating VVC are particularly noticeable in relation to changes to the vaginal mucosa that are microbiological, physiological and morphological in nature. In terms of antifungal, anti-inflammatory effects and mucosal repair, the effects of *L. crispatus* are similar to those of the commercial *L. delbrueckii* formulation. The promising results of this study highlighting the potential of *Lactobacillus* treatment of VVC in clinical practice require validation in well-designed clinical studies with larger sample sizes and long-term follow-up.
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